Researchers developed a gene-editing technology that reduces 'bad' cholesterol
A gene-editing treatment called VERVE-101 showed promising results in reducing cholesterol levels in patients with hereditary conditions.
The treatment used CRISPR editing techniques to turn off a cholesterol-raising gene in the liver, resulting in lower levels of LDL-C.
While the therapy has the potential to disrupt current high cholesterol treatments, further studies and FDA approval are needed before it can be widely available. [ more ]